Superior Cerebrovascular Outcomes with Tirzepatide versus Semaglutide in Diabetic CABG Patients: A Global Network Study of Propensity-Matched Patients.

No abstract is available for this paper.

• Publication year

  2025

• Venue

  Cardiovascular Drugs and Therapy

• Publication date

  2025-09-12

• Fields of study

  Medicine

• Identifiers
  DOI 10.1007/s10557-025-07757-3PMID 40938549
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Evaluating the Impact of Tirzepatide on Clinical Outcomes in Patients With Heart Failure

  2025cited by this paper
• The pleiotropic effects of glucagon-like peptide-1 receptor agonists in patients with metabolic dysfunction-associated steatohepatitis: a review for gastroenterologists

  2025cited by this paper
• Semaglutide: a key medication for managing cardiovascular-kidney-metabolic syndrome

  2025cited by this paper
• An Observational Study of Cardiovascular Outcomes of Tirzepatide vs Glucagon-Like Peptide-1 Receptor Agonists

  2025cited by this paper
• Semaglutide vs Tirzepatide for Weight Loss in Adults With Overweight or Obesity

  2024cited by this paper
• Glucagon-like Peptide 1, Glucose-Dependent Insulinotropic Polypeptide, and Glucagon Receptor Agonists in Metabolic Dysfunction-Associated Steatotic Liver Disease: Novel Medication in New Liver Disease Nomenclature

  2024cited by this paper
• Coronary artery bypass grafting (CABG) induces pro-inflammatory and immunomodulatory phenotype of platelets in the absence of a pro-aggregatory state.

  2024cited by this paper
• Risk of major adverse cardiovascular events and stroke associated with treatment with GLP-1 or the dual GIP/GLP-1 receptor agonist tirzepatide for type 2 diabetes: A systematic review and meta-analysis

  2024cited by this paper
• Effects of tirzepatide on circulatory overload and end-organ damage in heart failure with preserved ejection fraction and obesity: a secondary analysis of the SUMMIT trial

  2024cited by this paper
• Cardiovascular, Metabolic, and Safety Outcomes with Semaglutide by Baseline Age: Post Hoc Analysis of SUSTAIN 6 and PIONEER 6

  2024cited by this paper
• Clinical Outcomes of Tirzepatide or GLP-1 Receptor Agonists in Individuals With Type 2 Diabetes

  2024cited by this paper
• Diabetes and Stroke: What Are the Connections?

  2023cited by this paper
• Graft thrombosis after coronary artery bypass surgery and current practice for prevention

  2023cited by this paper
• Effect of glucagon-like peptide-1 receptor agonists administration during coronary artery bypass grafting: a systematic review and meta-analysis of randomized control trials.

  2023cited by this paper
• Effect of obesity on perioperative outcomes following gastrointestinal surgery: meta-analysis

  2023cited by this paper
• Comparison of Tirzepatide and Dulaglutide on Major Adverse Cardiovascular Events in Participants with Type 2 Diabetes and Atherosclerotic Cardiovascular Disease: SURPASS-CVOT Design and Baseline Characteristics.

  2023cited by this paper
• The Cardiovascular Effect of Tirzepatide: A Glucagon-Like Peptide-1 and Glucose-Dependent Insulinotropic Polypeptide Dual Agonist

  2023cited by this paper
• Impact of a dual glucose‐dependent insulinotropic peptide/glucagon‐like peptide‐1 receptor agonist tirzepatide on heart rate among patients with type 2 diabetes: A systematic review and pairwise and network meta‐analysis

  2023cited by this paper
• Tirzepatide reduces the predicted risk of atherosclerotic cardiovascular disease and improves cardiometabolic risk factors in adults with obesity or overweight: SURMOUNT‐1 post hoc analysis

  2023cited by this paper
• Morbid Obesity and Diabetes Increase the Risk of Reoperation following Microvascular Decompression: A National Surgical Quality Improvement Program Analysis of 1,303 Patients

  2023cited by this paper
• Association of Diabetes Mellitus With Postoperative Complications and Mortality After Non-Cardiac Surgery: A Meta-Analysis and Systematic Review

  2022cited by this paper
• Tirzepatide cardiovascular event risk assessment: a pre-specified meta-analysis

  2022cited by this paper
• Impact of obesity and diabetes on postoperative outcomes following surgical treatment of nontraumatic subarachnoid hemorrhage: Analysis of the ACS-NSQIP Database.

  2022cited by this paper
• Efficacy and Safety of Tirzepatide in Adults With Type 2 Diabetes: A Perspective for Primary Care Providers.

  2022cited by this paper
• SGLT2 inhibitors and GLP-1 receptor agonists: established and emerging indications.

  2021cited by this paper
• Effects of GLP-1 receptor agonists and SGLT-2 inhibitors in heart transplant patients with type 2 diabetes: Initial report from a cardiometabolic center of excellence.

  2021cited by this paper
• Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes.

  2021cited by this paper
• Revascularization for Coronary Artery Disease: Principle and Challenges.

  2020cited by this paper
• Metabolic and cardiovascular benefits of GLP-1 agonists, besides the hypoglycemic effect (Review).

  2020cited by this paper
• Pleiotropic Effects of GLP-1 and Analogs on Cell Signaling, Metabolism, and Function

  2018cited by this paper
• Empagliflozin in the management of diabetes mellitus after cardiac transplantationResearch Correspondenceretain-->.

  2017cited by this paper
• Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes.

  2016cited by this paper
• Sudden Thrombosis in Coronary Artery Bypass Grafting Surgery

  2015cited by this paper
• Coronary artery disease and diabetes mellitus.

  2014cited by this paper
• Diabetes and survival after coronary artery bypass grafting: comparison with an age- and sex-matched population.

  2010cited by this paper
• Diabetes and coronary artery bypass surgery: an examination of perioperative glycemic control and outcomes.

  2003cited by this paper
• Biphasic pro‐thrombotic and inflammatory responses after coronary artery bypass surgery

  2003cited by this paper
• The role of PCI and CABG in the management of coronary artery disease in patients with diabetes

  2002cited by this paper
• Diabetes and decline in heart disease mortality in US adults.

  1999cited by this paper

• Superior Cerebrovascular Outcomes with Tirzepatide Versus Semaglutide: A Call for Cautious Interpretation of Observational Data.

  2025cites this paper
• Comment on "Superior Cerebrovascular Outcomes with Tirzepatide Versus Semaglutide in Diabetic CABG Patients: A Global Network Study of Propensity-Matched Patients".

  2025cites this paper
• Response To "Superior Cerebrovascular Outcomes with Tirzepatide Versus Semaglutide: A Call for Cautious Interpretation of Observational Data".

  2025cites this paper